What is ImmuCell?
ImmuCell Corporation, listed on the Nasdaq under the ticker ICCC, operates at the intersection of biotechnology and agricultural efficiency. The firm is primarily recognized for its flagship product, First Defense, which provides essential immediate immunity to newborn calves. Beyond its established market presence, the company is currently in the advanced stages of developing Re-Tain, a pioneering treatment for subclinical mastitis. This innovation is particularly significant as it offers a non-antibiotic alternative for dairy cows, effectively eliminating the need for milk discard periods and addressing a major pain point in modern dairy operations. Through these scientific advancements, ImmuCell maintains a robust competitive advantage in the veterinary pharmaceutical landscape.
How much funding has ImmuCell raised?
ImmuCell has raised a total of $32.6M across 8 funding rounds:
Stock Offering
$5.9M
Share Placement
$3.5M
Multiple Rounds
$10.3M
Stock Offering
$8.3M
Debt
$350K
Share Placement
$4.3M
Stock Issuance/Offering (2016): $5.9M with participation from Undisclosed
Share Placement (2016): $3.5M led by Undisclosed
Debt (2017): $6.5M supported by TD Bank N.A
Private Equity (2017): $1.1M featuring Sandra F. Pessin and Brian L. Pessin
Stock Issuance/Offering (2017): $2.7M backed by Craig-Hallum Capital Group
Stock Issuance/Offering (2019): $8.3M with participation from Craig-Hallum Capital Group
Debt (2020): $350K led by PPP
Share Placement (2021): $4.3M, investors not publicly disclosed
Key Investors in ImmuCell
Craig-Hallum Capital Group
A full-service investment bank specializing in growth-oriented companies and providing strategic capital to emerging market leaders.
TD Bank N.A
A major financial institution providing diverse banking services and debt financing solutions to support corporate growth initiatives.
Sandra F. Pessin
A private investor providing equity backing to support the long-term development of specialized veterinary health technologies.
What's next for ImmuCell?
With the recent capital injection, ImmuCell is well-positioned to accelerate the commercialization of its pipeline assets. The strategic focus remains on the final development and regulatory navigation for Re-Tain, which represents a transformative opportunity to disrupt traditional mastitis treatment protocols. As the company transitions from a research-heavy phase to a broader market penetration strategy, investors are closely monitoring the scalability of its manufacturing capabilities and the adoption rates of its immunity-focused product suite. The firm's ability to maintain its growth trajectory will depend on its success in navigating the complex regulatory environment while expanding its footprint in the global dairy and beef cattle markets.
See full ImmuCell company page
